- Home
- VRAX vs CWD Comparison
VRAX vs CWD Comparison
Compare VRAX & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- CWD
- Stock Information
- Founded
- VRAX 2013
- CWD 2009
- Country
- VRAX United Kingdom
- CWD United States
- Employees
- VRAX N/A
- CWD N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CWD Real Estate
- Sector
- VRAX Health Care
- CWD Finance
- Exchange
- VRAX Nasdaq
- CWD Nasdaq
- Market Cap
- VRAX 4.4M
- CWD 4.5M
- IPO Year
- VRAX 2022
- CWD 2023
- Fundamental
- Price
- VRAX $0.67
- CWD $4.09
- Analyst Decision
- VRAX Strong Buy
- CWD
- Analyst Count
- VRAX 1
- CWD 0
- Target Price
- VRAX $3.00
- CWD N/A
- AVG Volume (30 Days)
- VRAX 165.6K
- CWD 2.4M
- Earning Date
- VRAX 01-01-0001
- CWD 11-11-2025
- Dividend Yield
- VRAX N/A
- CWD N/A
- EPS Growth
- VRAX N/A
- CWD N/A
- EPS
- VRAX N/A
- CWD N/A
- Revenue
- VRAX $6,331.00
- CWD $32,323,000.00
- Revenue This Year
- VRAX $217,274.83
- CWD N/A
- Revenue Next Year
- VRAX N/A
- CWD $56.47
- P/E Ratio
- VRAX N/A
- CWD N/A
- Revenue Growth
- VRAX N/A
- CWD N/A
- 52 Week Low
- VRAX $0.52
- CWD $1.63
- 52 Week High
- VRAX $3.62
- CWD $48.00
- Technical
- Relative Strength Index (RSI)
- VRAX 53.05
- CWD 43.71
- Support Level
- VRAX $0.64
- CWD $3.60
- Resistance Level
- VRAX $0.68
- CWD $4.50
- Average True Range (ATR)
- VRAX 0.03
- CWD 0.37
- MACD
- VRAX 0.01
- CWD -0.20
- Stochastic Oscillator
- VRAX 81.11
- CWD 25.39
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.